215 related articles for article (PubMed ID: 37971985)
21. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
Hong SH; Shepherd MD; Scoones D; Wan TT
J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
[TBL] [Abstract][Full Text] [Related]
22. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
[TBL] [Abstract][Full Text] [Related]
23. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
24. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
25. Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?
Beall RF; Hollis A; Kesselheim AS; Spackman E
Value Health; 2021 Sep; 24(9):1328-1334. PubMed ID: 34452713
[TBL] [Abstract][Full Text] [Related]
26. A cheat sheet to navigate the complex maze of pharmaceutical exclusivities in Europe.
Tomas MC; Peng B
Pharm Pat Anal; 2017 Jul; 6(4):161-170. PubMed ID: 28696178
[TBL] [Abstract][Full Text] [Related]
27. Effect of Evergreened Reformulations on Medicaid Expenditures and Patient Access from 2008 to 2016.
Dickson S
J Manag Care Spec Pharm; 2019 Jul; 25(7):780-792. PubMed ID: 30799664
[TBL] [Abstract][Full Text] [Related]
28. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
29. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
Rodriguez-Monguio R; Seoane-Vazquez E
AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
[TBL] [Abstract][Full Text] [Related]
30. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
31. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.
Wolff ME
J Pharm Sci; 2011 Aug; 100(8):3044-3054. PubMed ID: 21472728
[TBL] [Abstract][Full Text] [Related]
32. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
33. How drug life-cycle management patent strategies may impact formulary management.
Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
[TBL] [Abstract][Full Text] [Related]
34. Strategies That Delay Market Entry of Generic Drugs.
Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
[TBL] [Abstract][Full Text] [Related]
35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
36. Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades.
Amin T; Kesselheim AS
Health Aff (Millwood); 2012 Oct; 31(10):2286-94. PubMed ID: 23048110
[TBL] [Abstract][Full Text] [Related]
37. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
38. Teva v. Eisai: what's the real "controversy"?
Wang GL
Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
[TBL] [Abstract][Full Text] [Related]
39. Federal government-interest patent disclosures for recent top-selling drugs.
Long G
J Med Econ; 2019 Dec; 22(12):1261-1267. PubMed ID: 31190582
[No Abstract] [Full Text] [Related]
40. Examination of risk evaluation and mitigation strategies and drug safety in the US.
Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
